NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner
Fig 6
Predicted ligand-target interactions of the four compounds with the BTB domain of KEAP1.
Ligand-target modeling studies of the compounds with the active site of the BTB domain of KEAP1 containing the functionally critical Cys151 (marked with a white asterisk *). Predicted binding energies are shown in Table 2. 3D models and the corresponding 2D interaction diagrams are shown in A,B (SEL); C,D (4OI); E,F (SFN); G,H (BARD C1); and I,J (BARD C9). * = Cys151.